Kenneth Gordon, Professor of Dermatology at Northwestern University, talks about the oral medication apremilast, recently approved for psoriatic arthritis. Apremilast offers a major benefit to patients — especially those who don’t want an injectable medication. Its response rates are high and it is very well tolerated.
More like this
- Psoriasis Patients’ Options Include Effective Oral and Injectible Drugs
- Apremilast in DMARD-Naïve Patients With Psoriatis Arthritis: PALACE 4 (Phase 3)
- A Phase II Trial Finds Ixekizumab “Extremely Effective” and Safe for Psoriasis
- First Oral Medication OK’d To Fight Psoriatic Arthritis
- The ‘Heartbreak of Psoriasis’ Has Met Its Match!
Our other journal
P&T Journal for October 2014
FEATURES
The Clinical Trial Model Is Up for Review
Pyrazinamide-Induced Hyperuricemia
Lung Cancer Research Is Taking On New Challenges
Medical Applications for 3D Printing: Current and Projected Uses
PIPELINE PLUS
Steady Progress on Parkinson’s Disease
DEPARTMENTS
MEDICATION ERRORS
Telling True Stories Is an ISMP Hallmark
PRESCRIPTION: WASHINGTON
FDA Accepts Its First Biosimilar Application
New Drugs/Drug News/New Medical Devices
Pharmaceutical Approval Update
DRUG FORECAST
Edoxaban: an Investigational Factor Xa Inhibitor
Paul Lendner ist ein praktizierender Experte im Bereich Gesundheit, Medizin und Fitness. Er schreibt bereits seit über 5 Jahren für das Managed Care Mag. Mit seinen Artikeln, die einen einzigartigen Expertenstatus nachweisen, liefert er unseren Lesern nicht nur Mehrwert, sondern auch Hilfestellung bei ihren Problemen.